Patents Examined by Matthew P Coughlin
  • Patent number: 10233179
    Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: March 19, 2019
    Assignee: Abbvie Inc.
    Inventors: Iok Chan Ng, M-akhteruzzaman Molla, Tami J. Pilot-Matias, Anil Vasudevan, Tatyana Dekhtyar, Artour Gomtsian, Kathy Sarris, Ana Aguirre, Mikhail Chafeev
  • Patent number: 10233161
    Abstract: Provided herein are pharmaceutical compositions, which comprise a 1,2,4-oxadiazole benzoic acid or a pharmaceutically acceptable salt thereof. Further provided herein are certain pharmaceutically acceptable salts of a 1,2,4-oxadiazole benzoic acid and methods for making the same. Further provided herein are methods of treating or preventing a disease associated with a nonsense mutation or a premature stop codon, comprising administering such pharmaceutical compositions or pharmaceutically acceptable salts to a patient having a disease associated with a nonsense mutation or a premature stop codon.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: March 19, 2019
    Assignee: PTC Therapeutics, Inc.
    Inventors: Marla L. Weetall, Ellen Welch, Mandar V. Dali, James Takasugi
  • Patent number: 10233188
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: March 19, 2019
    Assignee: Pfizer Inc.
    Inventors: Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic
  • Patent number: 10227314
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 12, 2019
    Assignee: SOVA PHARMACEUTICALS, INC.
    Inventors: Sergio G. Durón, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein
  • Patent number: 10227286
    Abstract: Disclosed are compounds of Formula I, including all stereoisomers and salts thereof, wherein Q1, Q2 and R are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula I, comprising contacting a compound of Formula II with a compound of Formula III optionally in the presence of a catalyst or a base to form a compound of Formula I. Further disclosed is a method for preparing a compound of Formula IV, comprising reductively cyclizing a compound of Formula I in the presence of a reducing agent.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: March 12, 2019
    Assignee: FMC Corporation
    Inventor: Andrew Duncan Satterfield
  • Patent number: 10220024
    Abstract: An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. A cancer cell inhibitory drug containing at least a compound represented by general formula (1).
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 5, 2019
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Tsuyoshi Nomoto, Kohei Watanabe, Takeshi Miyazaki, Toshio Tanaka, Yasuhito Shimada, Yuhei Nishimura
  • Patent number: 10219986
    Abstract: A method of forming a stabilized calcium phosphate moiety for use in dental or biomedical applications includes providing a solution or dispersion including a calcium salt and reacting an organic phosphate having a polymerizable methacrylate or vinyl group with the solution or dispersion in order to form the calcium phosphate moiety having at least one pendant polymerizable group and at least one organic functional group, which may be the same group. A polymerizable composite system having a stabilized calcium phosphate formed according to the method is also provided.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: March 5, 2019
    Assignee: Modern Ideas LLC
    Inventors: Sunny Skaria, Kenneth Berk
  • Patent number: 10206902
    Abstract: The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Patent number: 10179862
    Abstract: An optically clear biofouling resistant coating compositions specially formulated for very high light transmission and more particularly coating compositions which can be applied to marine instruments and sensors. The compositions provide a biofouling resistant coating on the surface of the marine instruments and sensors which prevents underwater organisms from adhering and growing on the surfaces of the structures over a long period of time.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 15, 2019
    Assignees: Severn Marine Technologies, LLC, Mid-Mountain Materials, Inc.
    Inventors: Henry Lobe, John Knapp, Amulya K. Das, Gary Moffat
  • Patent number: 10179834
    Abstract: The disclosure relates to biodegradable polyether network polymers crosslinked via ester linkages, to substrates, implants and scaffolds comprising the biodegradable polyether network polymers, to methods for preparing such network polymers, implants and scaffolds, and to methods of using substrates, implants and scaffolds comprising the network polymers, particularly for culturing cells and regenerating tissue.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 15, 2019
    Assignee: The University of Melbourne
    Inventors: Anton Blencowe, Berkay Ozcelik, Greg Guanghua Qiao
  • Patent number: 10173989
    Abstract: The present invention relates to synthetic methods for 1,2,4-oxadiazole compounds. The general synthetic scheme is: R1 represents ?CH2OtBu or ?CH(CH3)OtBu, R3 represents ?CH2C(O)NHCPh3, ?CH2CH2C(O)NHCPh3, ?CH2C(O)OtBu, or ?CH2CH2C(O)OtBu, and Aaa is an amino acid residue selected from Thr and Ser; wherein the C-terminus thereof is esterified, and wherein the hydroxy moiety of the side chain of Thr or Ser is substituted with tbutyl; the base is triethylamine; and the solvent is tetrahydrofuran.
    Type: Grant
    Filed: September 24, 2017
    Date of Patent: January 8, 2019
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Patent number: 10173990
    Abstract: Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: January 8, 2019
    Assignees: Nippon Chemiphar Co., Ltd., J-Pharma Co., Ltd., DeThree Res. Lab. Inc.
    Inventors: Tsuyoshi Endo, Kunio Kobayashi, Hiroto Tanaka, Daisuke Saito, Masuharu Hirano, Hitoshi Endou, Naohiko Anzai
  • Patent number: 10159674
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 25, 2018
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Patent number: 10160753
    Abstract: The present invention provides indazole compounds of formula (I), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein Z1, Z2, R1, R2, R3, ‘m’ and ‘n’ have the meanings given in the specification, and pharmaceutically acceptable salts or stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of the compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: December 25, 2018
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Venkateshwar Rao Gummadi, Susanta Samajdar, Ajay Gupta
  • Patent number: 10155731
    Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: December 18, 2018
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.
    Inventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie, Miki Hirai
  • Patent number: 10150779
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: December 11, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Andrew Wasmuth, Donald W. Landry
  • Patent number: 10144734
    Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: December 4, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, James Collier, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Ginelle A. Ramann, Tony P. Tang, Li Ren, Shane M. Walls
  • Patent number: 10138216
    Abstract: Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: November 27, 2018
    Assignee: The University of Toledo
    Inventors: Viranga Tillekeratne, William Taylor, Sara Fedorka
  • Patent number: 10141516
    Abstract: Provides herein are a compound capable of improving light emitting efficiency, stability, and lifespan of the element, an organic element using the same, and an electric device for the same.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: November 27, 2018
    Assignee: DUK SAN NEOLUX CO., LTD.
    Inventors: Bumsung Lee, Yeonhee Choi, Daesung Kim, Soungyun Mun, Jungcheol Park, Kiho So, Jinho Yun, Daehwan Oh, Seungwon Yeo
  • Patent number: 10125121
    Abstract: The invention relates to new selective FYN kinase inhibitors of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of pain and arthritis, including osteoarthritis and rheumatoid arthritis.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: November 13, 2018
    Assignee: ROTTAPHARM BIOTECH S.R.L.
    Inventors: Roberto Artusi, Gianfranco Caselli, Lucio Rovati